by Plus Therapeutics | Jul 22, 2025 | GBM
Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”,...
by Plus Therapeutics | Jul 16, 2025 | GBM
As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...
by Plus Therapeutics | Jul 16, 2025 | GBM
Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide. At Plus Therapeutics, we...
by Plus Therapeutics | Jun 16, 2025 | GBM
We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...
by Plus Therapeutics | Jun 16, 2025 | GBM
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
by Plus Therapeutics | Jun 10, 2025 | GBM
At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal...
Recent Comments